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number tandem repeat analysis (MLVA) is increasingly in use.
However, no speciﬁc internationally agreed guidance is available.
Thirty M. pneumoniae DNA samples including serial dilutions of a
type strain were sent to six international laboratories to perform
MLVA and results were compared. Good correlation was
observed, indicating that this methodology can be robustly
performed in multiple sites. However, differences due to
interpretation of fragment size, repeat sequence identiﬁcation and
repeat numbering led to inconsistency in the ﬁnal proﬁles
assigned by laboratories. We propose guidelines for interpreting
M. pneumoniae MLVA typing and assigning the number of repeats.
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should be considered ﬁrst authorIntroductionMycoplasma pneumoniae causes human respiratory tract in-
fections [1]. Typing of isolates and positive clinical samples is
necessary to support epidemiologic data for the detection of
outbreaks and understand the transmission of infection. In
contrast to typing based on sequence differences in the P1 gene
of M. pneumoniae [2], multiple-locus variable-number tandem
repeat analysis (MLVA) is reportedly highly discriminatory [3]
and is now increasingly in use for strain characterization
internationally [4–11]. Investigating the ﬁve loci selected
(MPN1, MPN13–16), it has been reported that the MPN1 locus
is not stable, thus calling into question the reliability of the
marker [12]. Therefore, several authors have proposed an
alteration to the naming system to reﬂect this [12,13]. Despite
the availability of general guidelines for the MLVA procedure
[14,15], speciﬁc internationally agreed guidelines for the
execution and interpretation of MLVA of M. pneumoniae are
not yet available.
In this study, 24 M. pneumoniae clinical isolates were
included, as well as the reference strain M129 (ATCC 29342).
The clinical isolates, all derived from sputum specimens, were
obtained from the Public Health England Respiratory and Vac-
cine Preventable Bacteria Reference Unit culture collection.
DNA was extracted from bacterial cultures in Mycoplasma
liquid medium (Mycoplasma Experience Ltd., UK) using the
MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche). The
commercial quantitative type strain NCTC10119 FH (Minerva
Biolabs) was used to determine sensitivity of MLVA at four
dilutions (1000, 100, 10 and 1 copy/μL). MLVA was performed
in a blinded manner using a previously described method [3] in
six international laboratories (China, England, France, Germany,
Netherlands, United States of America). Results were collated,
including fragment size, calculated MLVA repeat number and
MLVA proﬁle. No guidelines were given to the participating
laboratories other than that already available in the literature.
Naming of proﬁles was based on the method in which naming isNew Microbe and New Infect 2015; 7: 37–40
er Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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38 New Microbes and New Infections, Volume 7 Number C, September 2015 NMNIbased on a string of allele numbers in the order MPN1, MPN13,
MPN14, MPN15, MPN16 showing the actual number of repeats
at each locus [5]. ‘No ampliﬁcation’ was assigned to loci that
failed to amplify [16].g
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.Regarding fragment sizes, excellent parity was seen among
laboratories, with <7 bp difference in fragment sizes between
all DNA samples and all laboratories. Table 1 includes ex-
pected fragment size and repeat numbers in order to clarify
predicted fragment size and repeat number. Regarding the
fragment repeat numbers, a total of three errors on assigning
and collating the MLVA repeat number from the accurate
fragment size (transcription errors) were noted from two
separate laboratories (Table 2). In addition, there was an
inconsistency in the results reported for two of the loci,
MPN13 and MPN15. This was due to a different interpretation
of fragment repeat number when encountering a point num-
ber. Speciﬁcally, four of the laboratories rounded 3.2 copies
up to 4 repeats for MPN13, whereas two other laboratories
rounded <3.5 down to 3 repeats. This highlights the need for
an internationally agreed protocol regarding the interpretation
of MLVA repeat numbers. In addition, one laboratory made
calculating errors linked to the determination of the sequence
of MPN15. The MPN15 sequence was manually determined as
TGTCCATTTTTACTTCCATCAT, in contrast to the accurate
TTGTCCATTTTTTCTTCCATC sequence calculated using
tandem repeat ﬁnder software with settings match, mismatch,
indel of (2,3,5). It should be noted that the use of settings other
than (2,3,5) can give alternative repeat sequence and length
for some loci. For example, using settings (2,7,7) for
M. pneumoniae M129, the MPN15 repeat would be only 20 bp
with a different sequence (TTGTCCATTTTTTTTCCATC
instead of TTGTCCATTTTTTCTTCCATC).
Excluding the three transcription errors, and after correcting
for interpretation differences by rounding up partial repeat
numbers to the next integer value, all laboratories determined
identical fragment repeat numbers for the M129 strain, and 20
of the 24 clinical isolates gave consistent fragment repeat
numbers (Table 2). Actual technical differences were seen in
only four samples: samples 8, 10, 21 and 30. Interestingly, these
samples had lower-than-average DNA concentration on initial
DNA extraction (less than 3 μg/mL DNA, compared to 7 μg/
mL for the other samples). To compare the sensitivity, a serial
dilution of the NCTC10119 strain was included. All labora-
tories determined the MLVA proﬁle in the presence of
1000 copies/μL. However, only three laboratories obtained a
full proﬁle, while the other three reported partial proﬁles forCrown Copyright © 2015 New Microbes and New Infections published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 37–40
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 2. MLVA proﬁles collated from six international laboratories after investigation of 30 Mycoplasma pneumoniae DNA
samples
Sample Expected proﬁlea Lab 1 Lab 2 Lab 3 Lab 4 Lab 5 Lab 6
1 (M129) 44572 44572 43562 44572 44572 44572 43562
2 (1000 copies/μL)b 43662 43662 42652 43662 43662 43662 42652
3 (100 copies/μL) 43662 43662 42652 4–662 4356 -c 43662 - 255c -
4 (10 copies/μL) 43662 43662 - - 652 4–6-2 - - - - - 43662 - - - - -
5 (1 copy/μL) 43662 - - - - - - - - - - - - 6 - - - - - - - - - - - - - - - - -
6 43662 43662 42652 43662 43662 43662 42652
7 43662 43662d 42652 43662 43662 43662 42652
8 53662 63662c 52652 53662 53662 53662 52652
9 54572 54572 53562 54572 54572 54572 53562
10 63662 63662 62652d 63662 63662 63662 62542c
11 34572 34572 33562 34572 34572 34572 33562
12 (M129) 44572 44572 43562 44572 44572 44572 43562
13 63562 63562 62552d 63562 63562 63562 62552
14 33562 33562 32552 33562 33562 33562 32552
15 63562 63562 62552 63562 63562 63562 62552
16 53662 53662 52652 53662 53662 53662 52652
17 23662 23662 22652 23662 23662 23662 22652
18 44572 44572 43562 44572 44572 44572 43562
19 23562 23562 22552 23562 23562 23562 22552
20 43572 43572 42562 43572 43572 43572 42562
21 54572 54572 53562 54572 54572 54572 53542c
22 54572 54572 53562 54572 54572 54572 53562
23 43662 43662 42652 43662 43662 43662 42652
24 34572 34572 33562 34572 34572 34572 33562
25 63562 63562 62552 63562 63562 63562 62552
26 34572 34572 33562 34572 34572 34572 33562
27 33662 33662 32652 33662 33662 33662 32652
28 23662 23662 22652 23662 23662 23662 22652
29 33662 33662 32652 33662 33662 33662 32652
30 54572 - - - - - - - - - - 54572 5–572 54572 - - 562c
Repeat number different from the expected result are underlined. A hyphen indicates no ampliﬁcation.
MLVA, multiple-locus variable-number tandem repeat analysis.
aNaming of proﬁles was based on the method in which naming is based on a string of allele numbers in order of MPN1, MPN13, MPN14, MPN15 and MPN16 showing the actual
number of repeats at each locus.
bSamples 2, 3, 4 and 5 are dilutions of the NTCT10119 FH commercial standard strain with 1000, 100, 10 and 1 copies/μL, respectively.
cMLVA proﬁle remains different from the expected MLVA proﬁle after correction for transcription errors and interpretation differences.
dMLVA proﬁles with initial transcriptional errors.
NMNI Chalker et al. International M. pneumoniae MLVA study 39the 100 copies/μL standard; two of these partial proﬁles
differed in the repeat number for MPN14. A full proﬁle was
obtained with the 10 copies/μL standard by only two labora-
tories. None of the laboratories obtained a full proﬁle for the
lowest dilution tested (1 copy/μL). When examining both the
serial dilution and the low-loaded sample results, it was
apparent that in laboratory 5, which increased the number of
ampliﬁcation cycles to 45 for samples that gave poor results
with 25 cycles of ampliﬁcation, the typing method showed a
greater sensitivity.DiscussionThis study highlights the need for standardization of interpre-
tive criteria for data analysis internationally. It indicates that
comparison of existing published MLVA data between labora-
tories may be ﬂawed in some cases, diminishing reliability of
strain investigation involving more than one laboratory. The
following recommendations are considered pertinent by our
collaborative group in enabling standardization of interpretive
data.Crown Copyright © 2015 New Microbes and New Infections published by Elsevier Ltd on beha
This is an open access artiFirst, predicted fragment sizes and repeat numbers should be
assigned using the information provided in Table 1. Sequence of
repeat fragments listed in Table 1 should be considered as the
sequence of interest.
Second, If tandem repeat ﬁnder software is used (http://
tandem.bu.edu/trf/trf.html) [17] to determine repeat numbers,
the following settings should be used: match, mismatch, indel
(2,3,5).
Third, the repeat number should be expressed as whole in-
tegers, and partial sequences should be rounded up to the next
integer number. The rounding up or down convention is matter
of debate [14,15]. However, as previously reported [15],
rounding the partial number of repeats up and not down will
avoid rounding down to zero a repeat number such as 0.7, which
is ambiguous, as it may be understood as ‘lack of repeat.’ Thus,
using a ‘rounding up’ convention, zero will unambiguously be
deﬁned as ‘lack of repeat.’ Moreover, by retaining a rounding-up
approach, future data will correspond with historical data in
previous publications related to M. pneumoniae MLVA typing.
Fourth, the MPN1 target should be removed from future
analyses due to its instability [12,13]. The identiﬁcation of addi-
tional MLVA targets that have greater stability than target MPN1lf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 37–40
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
40 New Microbes and New Infections, Volume 7 Number C, September 2015 NMNIand enable greater discrimination power than MPN16 should be
advanced. With the removal of the MPN1 allele, adoption of the
following naming system is recommended: MLVA-1, -2, -3 and
-4, where each digit corresponds to repeat numbers at loci
MPN13, MPN14, MPN15 and MPN16, respectively.
In conclusion, although whole genome sequencing has
become rapid and affordable to replace older typing methods in
the future for either clinical strains or clinical specimens [18],
MLVA typing using the method by Dégrange et al. [3] is widely
in use for M. pneumoniae. MLVA typing was performed with
good correlation in six international laboratories, indicating
that this methodology can be correctly performed on
M. pneumoniae at different locations. Differences due to inter-
pretation of fragment size, repeat sequence identiﬁcation and
repeat numbering led to inconsistencies in the ﬁnal proﬁles
assigned by laboratories. With users following the interpreta-
tion guidelines we provide, full interlaboratory strain compar-
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